Huadong Medicine Co.Ltd(000963) : kaglitazin tablets and liraglutide injection are expected to be approved for listing this year

Huadong Medicine Co.Ltd(000963) ( Huadong Medicine Co.Ltd(000963) ) said that the company’s products for treatment of diabetes, and Liraglutide Injection is expected to be approved this year. In addition, the company’s sitagliptin metformin tablets will be put on the market as early as July 2022 after the expiration of the original research patent. Arcalyst, a recently introduced product that has been listed abroad, has been listed in the list of overseas drugs in urgent need of clinical treatment (the first batch) by CDE for the treatment of cold pyrroline related periodic syndrome, which is also expected to accelerate the listing progress in China.